Ninenovo Blood Oxygen Ring (BORMB-01-6,BORMB-01-7,BORMB-01-8,BORMB-01-9,BORMB-01-10,BORMB-01-11,BORMB-01-12,BORMB-01-13,BORMB-01-14)

K260490 · Shenzhen Ninenovo Technology Limited · DQA · Oct 2, 2026 · Cardiovascular

Device Facts

Record IDK260490
Device NameNinenovo Blood Oxygen Ring (BORMB-01-6,BORMB-01-7,BORMB-01-8,BORMB-01-9,BORMB-01-10,BORMB-01-11,BORMB-01-12,BORMB-01-13,BORMB-01-14)
ApplicantShenzhen Ninenovo Technology Limited
Product CodeDQA · Cardiovascular
Decision DateOct 2, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.2700
Device ClassClass 2

Indications for Use

The Ninenovo Blood Oxygen Ring is a wireless, non-invasive, and stand-alone pulse oximeter intended to be used for spot-check and/or continuous data collection of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR) through the index finger in adult patients. It can be used in hospitals and home environments for up to twelve hours in non-motion and well perfused conditions. It is not intended for single-use and out-of-hospital transport use and does not have alarms.

Device Story

Wearable, non-invasive pulse oximeter ring; worn on index finger base. Uses red (660nm) and infrared (940nm) light to measure light absorption changes in oxyhemoglobin and reduced hemoglobin; calculates SpO2 and pulse rate. Device connects via Bluetooth 5.2 BLE to a mobile application for data display. Used by adults in home or hospital settings for spot-check or continuous monitoring (up to 12 hours). Provides SpO2 and PR data to users/clinicians to assist in physiological assessment. Benefits include convenient, non-invasive, continuous oxygen saturation tracking without requiring clinical staff presence.

Clinical Evidence

Prospective clinical study of 19 healthy adult volunteers (Fitzpatrick types I-VI, ages 18-45). 475 paired SpO2/SaO2 observations collected during steady-state, non-motion induced hypoxia (70-100% SaO2). Primary endpoint: SpO2 accuracy (Arms). Results: Arms < 3% across 70-100% range. Subgroup analyses by sex and skin pigmentation met acceptance criteria.

Technological Characteristics

Wearable ring form factor; titanium alloy outer, epoxy resin inner contact. Reflective pulse oximetry (660nm/940nm). Bluetooth 5.2 BLE connectivity. Powered by 3.7V Lithium battery. Complies with IEC 60601-1, IEC 60601-1-2, IEC 60601-1-11, and ISO 80601-2-61. Reusable, non-sterile.

Indications for Use

Indicated for adult patients requiring spot-check or continuous SpO2 and pulse rate monitoring via index finger. Used in hospital and home settings for up to 12 hours under non-motion, well-perfused conditions. Not for single-use, out-of-hospital transport, or patients requiring alarms.

Regulatory Classification

Identification

An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.

Predicate Devices

Reference Devices

Submission Summary (Full Text)

{1} **FDA** U.S. FOOD & DRUG ADMINISTRATION October 2, 2026 Shenzhen Ninenovo Technology Limited % Wilson Peng RA Manager Shenzhen Bosstar Consulting Company Limited. Rm. 1212, Wanjunhui Business Bldg., Xixiang Ave., Bao'An District Shenzhen, 518102 China Re: K260490 Trade/Device Name: Ninenovo Blood Oxygen Ring (BORMB-01-6, BORMB-01-7, BORMB-01-8, BORMB-01-9, BORMB-01-10, BORMB-01-11, BORMB-01-12, BORMB-01-13, BORMB-01-14) Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: DQA Dated: August 26, 2026 Received: August 26, 2026 Dear Wilson Peng: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {2} K260490 - Wilson Peng Page 2 If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. {3} K260490 - Wilson Peng Page 3 For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Bradley Q. Quinn -S Bradley Quinn Assistant Director DHT1C: Division of Anesthesia, Respiratory, and Sleep Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {4} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260490 | ? | | Please provide the device trade name(s). | | ? | | Ninenovo Blood Oxygen Ring(BORMB-01-6,BORMB-01-7,BORMB-01-8,BORMB-01-9,BORMB-01-10,BORMB-01-11,BORMB-01-12,BORMB-01-13,BORMB-01-14) | | | | Please provide your Indications for Use below. | | ? | | The Ninenovo Blood Oxygen Ring is a wireless, non-invasive, and stand-alone pulse oximeter intended to be used for spot-check and/or continuous data collection of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR) through the index finger in adult patients. It can be used in hospitals and home environments for up to twelve hours in non-motion and well perfused conditions. It is not intended for single-use and out-of-hospital transport use and does not have alarms. | | | | Please select the types of uses. | Prescription Use (21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C) | ? | {5} # 510(K) SUMMARY This summary of 510(K) safety and effective information is being submitted in accordance with the requirement SMDA and 21 CFR 807.92. ## 1. Submitter of 510(K): | Date of Prepared: | 20260930 | | --- | --- | | Submitter's Name: | Shenzhen Ninenovo Technology Limited | | Address: | B801, SZ-NELB, No. 20 Gaoxin S.7th Rd., Gaoxin District Community, Yuehai Subdistrict, Nanshan District, Shenzhen,518055, China | | Contact person: | Guoxing.Wang | | TEL: | +86-15001934371 | | Email: | guoxing.wang@ninenovo.com | | Date of Prepared: | 20260930 | | --- | --- | | Submitter's Name: | Shenzhen Bosstar Consulting Company Limited | | Address: | Room 1212, Wanjunhui Business Building, Xixiang Avenue, Bao'an District,Shenzhen City,Guangdong Province,China | | Contact person: | Mr. Wilson Peng | | TEL: | +86-13622380915 | | Email: | bcc2015319@163.com | ## 2. Proposed Device and code: | Device name: | Ninenovo Blood Oxygen Ring | | --- | --- | | Model: | BORMB-01-6, BORMB-01-7, BORMB-01-8, BORMB-01-9, BORMB-01-10, BORMB-01-11, BORMB-01-12, BORMB-01-13, BORMB-01-14 | 1 / 11 {6} | Classification product code: | DQA | | --- | --- | | Regulation number: | 21 CFR 870.2700 | | Regulation description: | Oximeter | | Review panel: | Cardiovascular | | Device class: | II | | Sterilization facility | Not applicable | | Type: | Traditional | ### 3. Predicate Device: Primary Predicate Device: | 510(K) | Trade or Proprietary or Model Name | Company | | --- | --- | --- | | K221361 | circul pro Ring | Hangzhou Megasens Technology Company, Ltd. | Reference Device: | 510(K) | Trade or Proprietary or Model Name | Company | | --- | --- | --- | | K191088 | Oxiband (Checkme) O2 Pulse Oximeter | Shenzhen Viatom Technology Co., Ltd. | ### 4. Description of Proposed Device: The Ninenovo Blood Oxygen Ring is a small, wearable, non-invasive wireless device. The Ring, which is of a smooth and a light design and is easy to be worn and taken off, is intended to be worn on the base of the index finger. In order to adapt the optical module with the user's skin, we designed multiple ring sizes (Inner diameter 16.5mm~23.1mm) for consumers to choose to fit different sizes of fingers. The sensor of the Ring should be placed on the palmar side of the proximal phalanx of the index finger and along the radial artery. Position the ring so that the sensors fit snugly on the base of your finger. It must remain in this position to optimize data collection although you can switch it between different fingers if needed. We recommend that you wear the ring on your index finger. If that is not the best fit for you, wear it on the finger you selected the size for. If the ring shifts during wear, please adjust it back into position. The Ninenovo Blood Oxygen Ring measures oxygen saturation by illuminating the skin and measuring changes in the light absorption of oxygenated (oxyhemoglobin) and deoxygenated blood (reduced hemoglobin) using light of two wavelengths: red and infrared. The ratio of absorbance at these wavelengths is calculated and calibrated against direct measurements of arterial oxygen saturation (SaO2) to establish the pulse oximeter's measurement of functional oxygen saturation of arterial hemoglobin (SpO2). 2 / 11 {7} | Model | Size: Inner diameter × Width ( in mm ) | Difference Description | | --- | --- | --- | | BORMB-01-6 | 16.5×7.8 | Inner diameter | | BORMB-01-7 | 17.4×7.8 | Inner diameter | | BORMB-01-8 | 18.2×7.8 | Inner diameter | | BORMB-01-9 | 19.0×7.8 | Inner diameter | | BORMB-01-10 | 19.9×7.8 | Inner diameter | | BORMB-01-11 | 20.7×7.8 | Inner diameter | | BORMB-01-12 | 21.5×7.8 | Inner diameter | | BORMB-01-13 | 22.3×7.8 | Inner diameter | | BORMB-01-14 | 23.1×7.8 | Inner diameter | | Remark: Besides of the inner diameter is different as the above, all other factor of the device is the same. | | | ● The device is not for life-supporting or life-sustaining, not for implant. ● The device is not provided sterile and is NOT a reprocessed single-use device. ● The device is a spot-check pulse oximeter and does not include alarms. ● The device does not support the measurement in the condition of low perfusion. ● The device is reusable and does not need sterilization. ## 5. Indications for Use The Ninenovo Blood Oxygen Ring is a wireless, non-invasive, and stand-alone pulse oximeter intended to be used for spot-check and/or continuous data collection of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR) through the index finger in adult patients. It can be used in hospitals and home environments for up to twelve hours in non-motion and well perfused conditions. It is not intended for single-use and out-of-hospital transport use and does not have alarms. ## 6. Technical and Performance The following table compares the device to the predicate device with basic technological characteristics. Ninenovo Blood Oxygen Ring (Model: BORMB-01-6, BORMB-01-7, BORMB-01-8, BORMB-01-9, BORMB-01-10, BORMB-01-11, BORMB-01-12, BORMB-01-13, BORMB-01-14) has been compared to the circul pro Ring (K221361) as a Primary Predicate device and Oxiband (Checkme) O2 Pulse Oximeter(K191088) as a reference device for substantial equivalence. A table comparing the two devices is provided as follows: 3 / 11 {8} | Comparison Element | Subject Device Name | Primary Predicate Device (K221361) | Reference Device(K191088) | Comparison | | --- | --- | --- | --- | --- | | Basic Elements | | | | | | 510(k) | Pending | K221361 | K191088 | | | Device Name | Ninenovo Blood Oxygen Ring | circul pro Ring | Oxiband (Checkme) O2 Pulse Oximeter | / | | Device Model | BORMB-01-6, BORMB-01-7, BORMB-01-8, BORMB-01-9, BORMB-01-10, BORMB-01-11, BORMB-01-12, BORMB-01-13, BORMB-01-14 | | Oxiband | / | | Applicant | Shenzhen Ninenovo Technology Limited | Hangzhou Megasens Technology Company, Ltd. | Shenzhen Viatom Technology Co., Ltd. | / | | Classification Regulation | 21 CFR 870.2700 | 21 CFR 870.2700 | 21 CFR 870.2700 | same | | Classification and Code | Class II | Class II | Class II | same | | Classification Name | Oximeter | Oximeter | Oximeter | same | 4 / 11 {9} | Comparison Element | Subject Device Name | Primary Predicate Device (K221361) | Reference Device(K191088) | Comparison | | --- | --- | --- | --- | --- | | Product code | DQA | DQA | DQA | same | | Prescription or OTC | Prescription | Prescription | Prescription | same | | Indications for Use | The Ninenovo Blood Oxygen Ring is a wireless, non-invasive, and stand-alone pulse oximeter intended to be used for spot-check and/or continuous data collection of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR) through the index finger in adult patients. It can be used in hospitals and home environments for up to twelve hours in non- motion and well perfused conditions. It is not intended for single-use and out-of-hospital transport use and does not have alarms. | The circul™ pro Ring is a wireless, non-invasive, and stand-alone pulse oximeter intended to be used for spot-check and/or continuous data collection of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR) through the index in adult patients. It can be used in hospitals and home environments for up to twelve hours in non- motion and well perfused conditions. It is not intended for single-use and out-of-hospital transport use and does not have alarms. | The Oxiband Pulse Oximeter is a wrist pulse oximeter indicated for use in measuring, displaying, storing and transmitting functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate for adult patients. It is intended for spot-check and/or continuous data collection, and not continuous monitoring. It can be used in sleep labs, long-term care, hospitals and home use. | Same as Primary predicate device | | Technology | | | | | | Technology Type | Reflective Light | Reflective Light | Reflective Light | Same | 5 / 11 {10} | Comparison Element | Subject Device Name | Primary Predicate Device (K221361) | Reference Device(K191088) | Comparison | | --- | --- | --- | --- | --- | | Intended Application Site | Finger | Finger | Finger | same | | Measurement Wavelength | | | | | | Red | 660nm± 10nm | 660 nm ± 10 nm | Not Reported | same | | Infrared | 940nm± 20nm | 940 nm ± 20 nm | Not Reported | | | Performance | | | | | | Interface | Bluetooth 5.2 BLE | Bluetooth (BLE 4.1) | Bluetooth | same | | User Interface | Via mobile application | Via mobile application | Not reported | Same | | Battery | 3.7 V Lithium Battery | 3.7 V Lithium Battery | Lithium Rechargeable Battery | Same | | Power Supply Requirement | 5 V DC (minimum) | 5 V DC (minimum) | Not reported | Same | | SpO2 Measurement Range | 70% to 100% | 70% - 100% | Not reported | Same | | SpO2 Accuracy | 70% - 100%: ±2% 70%-80%: ± 3% | ± 3.5% (SpO2 within 70% - 100% range) | 70% - 100%: ±2% (Arms:1.88) 70%-80%: ± 3% | Different Note 1 | 6 / 11 {11} | Comparison Element | Subject Device Name | Primary Predicate Device (K221361) | Reference Device(K191088) | Comparison | | --- | --- | --- | --- | --- | | | 80%-90%: ± 2% 90%-100%: ± 2% 0%-69%: not defined | | 80%-90%: ± 2% 90%-100%: ± 2% 0%-69%: not defined | | | PR Measurement Range | 30 to 240 bpm | 30 bpm – 240 bpm | 30 bpm – 250 bpm | Same as the predicate device | | PR Accuracy | ±2 bpm or ±2% , whichever is greater | ± 2% or ± 2 bpm, whichever is greater | ± 2bpm or ± 2%, whichever is greater | same | | Atmospheric Pressure | 700 to 1060 hPa | 70 kPa – 106 kPa | 70 kPa – 106 kPa | same | | Operating Temperature | 5°C to 40°C | 5°C – 40°C | 5°C – 40°C | same | | Relative Humidity | 10% to 95% | 30% - 80% (non-condensing) | 10% - 95% | Same as reference device | | Storage Environment | -20 to 60°C 10% to 95% RH 700 to 1060 hPa | -10°C– 50°C Temperature 15%- 95% Relative Humidity (non-condensing) 70 kPa - 106 kPa Atmospheric | -25°C- 70°C | Different Note 2 | 7 / 11 {12} | Comparison Element | Subject Device Name | Primary Predicate Device (K221361) | Reference Device(K191088) | Comparison | | --- | --- | --- | --- | --- | | | | Pressure | | | | IP Classification | Charge case: IP22 Smart Ring: IP68 | IP65 | Not Reported | Different Note 3 | | Normal Service Life | 2 Years | 3 Years | Not Reported | Different Note 4 | | Contacting Materials | Outer : titanium alloy; Inner : epoxy resin | Stainless Steel, PC | Not Reported | Different Note 5 | # **Analysis for the differences:** # **Note 1** The SpO2 measurement accuracy of the subject device is similar to the SpO2 measurement accuracy of the predicate and reference devices. The SpO2 measurement of the subject device meets the requirements of the ISO 80601-2-61, so the difference does not affect the safety and effectiveness of the subject device. 8 / 11 {13} # Note 2 The storage environment conditions of the subject device fall within the range of the subject and reference devices and are expressed in the device labeling. The subject device met the requirements of IEC 60601-1, IEC 60601-1-11, and ISO 80601-2-61. The difference in storage conditions between the subject and predicate device does not raise new questions of safety or effectiveness. # Note 3 The subject device met the requirements of ISO 80601-2-61. The difference in ingress protection between the subject and predicate device does not raise new questions of safety or effectiveness. # Note 4 The subject device has a normal service life of 2 years, while the primary predicate device has a service life of 3 years. The subject device's 2-year service life is supported by battery cycle testing (537 cycles completed, equivalent to approximately 10.3 years of actual use based on 52.1 cycles/year) and component aging testing, which demonstrate that the device maintains its claimed performance (SpO2 and PR accuracy) throughout and beyond the 2-year service life. The difference in service life does not raise new questions of safety or effectiveness. # Note 5 The subject device uses titanium alloy for the outer surface and epoxy resin for the inner contact surface, while the primary predicate device uses stainless steel and PC. The biocompatibility of the subject device materials has been evaluated in accordance with ISO 10993-1 and found to be acceptable for the intended contact type and duration (cytotoxicity, sensitization, and irritation were assessed and passed). The difference in contacting materials does not raise new questions of safety or effectiveness. # Conclusion: The Ninenovo Blood Oxygen Ring has been found to be substantially equivalent to the Primary Predicate Device, circul pro Ring (K221361). The Ninenovo Blood Oxygen Ring also has similar SpO2 accuracy as the Reference Device, Oxiband (Checkme) O2 Pulse Oximeter (K191088). 9 / 11 {14} ## 1. Performance Testing: Performance data includes "Non-Clinical Data" and "Clinical Data", brief description of which are shown as below. ### 1.1 Non-Clinical Data: The following performance data were provided in support of the substantial equivalence determination. ### 1.2 Biocompatibility Testing The biocompatibility evaluation for the subject device was conducted in accordance with Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". As dictated by the nature of body contact (intact skin) and contact duration (long-term exposure (C), the following endpoints were evaluated for the patient-contacting components: - Cytotoxicity - Skin Sensitization - Skin Irritation ### 1.3 Electrical Safety and Electromagnetic Compatibility (EMC) The device(s) was assessed for conformity with the relevant requirements of the following standards and found to comply: - IEC 60601-1 Edition 3.2 2020-08 CONSOLIDATED VERSION Medical electrical equipment - Part 1: General requirements for basic safety and essential performance - IEC 60601-1-2 Edition 4.1 2020-09 CONSOLIDATED VERSION Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests - IEC 60601-1-11 Edition 2.1 2020-07 CONSOLIDATED VERSION Medical electrical equipment - Part 1-11: General requirements for basic safety and essential performance - Collateral Standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment ### 1.4 Bench Testing Bench testing was conducted on the subject device to verify its functional performance and measurement accuracy. Testing covered charging function, battery performance, Bluetooth transmission, SpO \( _{2} \) measurement range (70%–100%), and pulse rate measurement range (30–240 bpm). Component aging testing was also performed to simulate the end of the proposed service life, pulse rate accuracy remaining within specification. The device complies with the applicable requirements of IEC 60601-1-11:2015 and ISO 80601-2-61:2017. 10 / 11 {15} ## 1.5 Software Verification and Validation Testing In compliance with the requirements specified in the U.S. Food and Drug Administration (FDA) guidance document for industry and FDA staff - Content of Premarket Submissions for Device Software Functions - comprehensive Software Verification and Validation (V&V) testing has been completed for this product. Consistent with the Basic Documentation Level, the software documentation has been included in these 510(k) submissions, along with full test documentation. System testing results provided in this 510(k) demonstrate that all software requirement specifications have been met, and all software-related hazards have been mitigated to acceptable risk levels. ## 1.6 Clinical Data: Clinical studies were conducted to verify the accuracy of proposed device. The clinical studies were conducted per following standards: - ISO 80601-2-61 Second edition 2017-12 (Corrected version 2018-02) Medical electrical equipment - Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment - Pulse Oximeters-Premarket Notification Submissions: Guidance for Industry and Food and Drug Administration Staff The purpose of the clinical trial was to evaluate the SpO2 accuracy performance of the subject Pulse Oximeter during stationary (non-motion) conditions over a wide range of arterial blood oxygen saturation levels as compared to arterial blood CO-Oximetry. 19 healthy adult volunteer subjects (ages 18-45yr, with light to dark pigmentation (Fitzpatrick Types I-VI)) were included in the study conducted to evaluate the SpO2 accuracy performance of proposed devices. A total of 475 paired SpO2/SaO2 observations were collected. Each system was evaluated during steady state/non-motion conditions with various levels of induced hypoxia resulting in stable oxygen saturation levels between 100% and 70% SaO2. Arterial blood samples were drawn during simultaneous data collection from the test devices. The blood was immediately analyzed on reference CO-Oximetry providing functional SaO2 for the basis of the SpO2 accuracy comparison. The SpO2 accuracy performance results showed the pulse oximeter to have an Arms less than 3% during steady state conditions over the range of 70-100%. Subgroup analyses by skin pigmentation and sex were performed descriptively; all subgroups met the overall acceptance criterion. Based on the non-clinical and clinical performance as documented in the system development, the subject devices were found to be substantially equivalent to the predicate device. ## 2. Conclusions: The Ninenovo Blood Oxygen Ring has been found to be substantially equivalent to the Primary Predicate Device, circul pro Ring (K221361), with respect to indications, design, materials, function and performance. Meanwhile, testing documentation supplied in this submission demonstrates that any differences in their technological characteristics do not raise any new questions of safety or effectiveness. 11 / 11
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...